Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
NASDAQ:CGON
RESEARCH TOOLSreports
CG Oncology, Inc. (CGON) Stock Price & Analysis
61 Followers
CGON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.77 - $50.23
Previous Close$32.43
Volume393.04K
Average Volume (3M)691.73K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.90
Next Earnings
May 09, 2024EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume691,725
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$71.50Price Target Upside120.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
CG Oncology, Inc. News
Bulls Say, Bears Say
Bulls Say
Analyst UpgradeAnalyst upgrades CGON to Buy from Neutral, highlighting an attractive entry point for the de-risked asset with a significant upside to the price target.
Clinical Trial ResultsCretostimogene demonstrates a higher complete response rate compared to competitors, showcasing its potential in the market.
Market PotentialLarge commercial opportunity identified for cretostimogene in NMIBC, with Goldman Sachs estimating a market size of $2.5B.
Bears Say
Drug EfficacyThere is still a debate on the differentiation of cretostimogene's complete response rate when compared to TAR-200.
Regulatory Approval RiskThe number of efficacy evaluable patients for Ankva's approval is fewer than those for prior approvals of similar treatments.
Treatment Safety63% of patients experienced a treatment related adverse event.
---
Ownership Overview
15.78% Insiders
6.83% Mutual Funds
41.62% Other Institutional Investors
35.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $25.77 and its highest was $50.23 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
Currently, no data Available
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is May 09, 2024 which is 21 days ago.
How were CG Oncology, Inc.’s earnings last quarter?
Currently, no data Available
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -$0.31.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 66,640,150 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Among the largest hedge funds holding CG Oncology, Inc.’s share is Perceptive Advisors LLC. It holds CG Oncology, Inc.’s shares valued at 57M.
---
CG Oncology, Inc. Stock Smart Score
CGON Stock 12 Month Forecast
Average Price Target
$71.50
▲(120.68% Upside)
Technical Analysis
Best Analysts Covering CGON
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-13.60%
assigned a buy rating 21 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -13.60% per trade.
---